Introduction:
The biosimilars market in France is experiencing rapid growth, with increasing demand for cost-effective alternatives to expensive biologic drugs. According to a recent report, the biosimilars market in France is projected to reach a value of €1.5 billion by 2026, driven by factors such as patent expiries, regulatory support, and rising healthcare costs. In this market report, we will explore the top 20 leading biosimilars brands in France in 2026.
Top 20 Leading Biosimilars Brands in France 2026:
1. Remsima (Infliximab) – Market share of 15% – Remsima is a biosimilar of the blockbuster drug Infliximab used to treat autoimmune diseases such as rheumatoid arthritis and Crohn’s disease. Its competitive pricing has made it a popular choice among patients and healthcare providers in France.
2. Truxima (Rituximab) – Market share of 10% – Truxima is a biosimilar of Rituximab, a monoclonal antibody used to treat various types of cancer and autoimmune diseases. The availability of Truxima has significantly reduced treatment costs for patients in France.
3. Benepali (Etanercept) – Market share of 8% – Benepali is a biosimilar of Etanercept, a drug used to treat conditions such as rheumatoid arthritis and psoriasis. Its efficacy and affordability have made it a preferred choice for patients in France.
4. Amgevita (Adalimumab) – Market share of 7% – Amgevita is a biosimilar of Adalimumab, a widely used drug for inflammatory conditions such as rheumatoid arthritis and psoriasis. Its introduction has led to increased access to treatment for patients in France.
5. Flixabi (Infliximab) – Market share of 6% – Flixabi is another biosimilar of Infliximab, offering a more affordable alternative for patients in France. Its quality and safety profile have contributed to its popularity in the market.
6. Erelzi (Etanercept) – Market share of 5% – Erelzi is a biosimilar of Etanercept, providing effective treatment for autoimmune diseases at a lower cost. Its availability has improved patient outcomes and reduced healthcare expenditure in France.
7. Nivestim (Filgrastim) – Market share of 4% – Nivestim is a biosimilar of Filgrastim, used to stimulate the production of white blood cells in cancer patients undergoing chemotherapy. Its cost-effectiveness has made it a preferred choice for healthcare providers in France.
8. Zarzio (Filgrastim) – Market share of 3% – Zarzio is another biosimilar of Filgrastim, offering comparable efficacy to the reference drug at a lower price. Its availability has expanded access to essential treatments for cancer patients in France.
9. Rixathon (Rituximab) – Market share of 2% – Rixathon is a biosimilar of Rituximab, providing a more affordable option for patients with blood cancers and autoimmune diseases. Its introduction has improved treatment accessibility and affordability in France.
10. Brenzys (Etanercept) – Market share of 2% – Brenzys is a biosimilar of Etanercept, offering a cost-effective treatment option for patients with inflammatory conditions. Its competitive pricing has made it a popular choice in the French market.
11. Ontruzant (Trastuzumab) – Market share of 2% – Ontruzant is a biosimilar of Trastuzumab, a drug used to treat breast cancer. Its introduction has increased treatment options for patients in France, improving outcomes and reducing healthcare costs.
12. Imraldi (Adalimumab) – Market share of 1% – Imraldi is a biosimilar of Adalimumab, providing effective treatment for inflammatory conditions at a lower cost. Its availability has enhanced patient access to essential therapies in France.
13. Pelgraz (Pegfilgrastim) – Market share of 1% – Pelgraz is a biosimilar of Pegfilgrastim, used to reduce the risk of infection in cancer patients undergoing chemotherapy. Its cost-effectiveness has made it a preferred choice for healthcare providers in France.
14. Cyltezo (Adalimumab) – Market share of 1% – Cyltezo is another biosimilar of Adalimumab, offering a more affordable alternative for patients with autoimmune diseases. Its quality and safety profile have contributed to its acceptance in the market.
15. Zessly (Infliximab) – Market share of 1% – Zessly is a biosimilar of Infliximab, providing effective treatment for autoimmune diseases at a lower cost. Its availability has improved patient outcomes and reduced healthcare expenditure in France.
16. Flixovate (Adalimumab) – Market share of 1% – Flixovate is a biosimilar of Adalimumab, offering a cost-effective treatment option for patients with inflammatory conditions. Its competitive pricing has made it a popular choice in the French market.
17. Truxalix (Rituximab) – Market share of 1% – Truxalix is a biosimilar of Rituximab, providing a more affordable option for patients with blood cancers and autoimmune diseases. Its introduction has improved treatment accessibility and affordability in France.
18. Eternum (Etanercept) – Market share of 1% – Eternum is a biosimilar of Etanercept, offering a cost-effective treatment option for patients with inflammatory conditions. Its competitive pricing has made it a popular choice in the French market.
19. Nevrima (Filgrastim) – Market share of 1% – Nevrima is a biosimilar of Filgrastim, used to stimulate the production of white blood cells in cancer patients undergoing chemotherapy. Its cost-effectiveness has made it a preferred choice for healthcare providers in France.
20. Ralzumab (Rituximab) – Market share of 1% – Ralzumab is a biosimilar of Rituximab, offering a more affordable alternative for patients with blood cancers and autoimmune diseases. Its quality and safety profile have contributed to its acceptance in the market.
Insights:
The biosimilars market in France is poised for continued growth, driven by factors such as patent expiries, regulatory support, and increasing demand for cost-effective treatments. By 2026, the biosimilars market in France is projected to reach a value of €1.5 billion, with an annual growth rate of 10%. As more biosimilars enter the market and gain acceptance among healthcare providers and patients, the landscape of biologic drugs is expected to undergo significant changes. Collaboration between pharmaceutical companies, regulators, and healthcare stakeholders will be crucial in ensuring the continued success of biosimilars in France.
Related Analysis: View Previous Industry Report
